1 January 2019 in Urology Research and Practice
Objective: Medical expulsive therapy is an important non-invasive treatment modality that facilitates the passage of ureteral stones. The aim of the present study was to evaluate the efficacy of Gilaburu (Viburnum opulus) extract in the treatment of distal ureteral stones <10 mm. Material and methods: Data of 103 patients were retrospectively analyzed. Patients were divided into two groups: those given V. opulus 1000 mg peroral 3×2 and diclofenac 50 mg peroral on-demand (n=53) and those given only diclofenac sodium 50 mg peroral on-demand (n=50). Comparisons of stone expulsion rates and the elapsed time until the expulsion between the groups were determined as primary outcome measures. The comparison of the need for additional treatment [ureteroscopy (URS) or extracorporeal shock wave lithotripsy (ESWL)], the need for emergency admission, analgesic requirement, and the complication rates in additional treatment were determined as secondary outcome measures. Results: The mean age of the patients was 45.8±14.5 years. The rate of stone expulsion was significantly higher (82% vs. 66%, p=0.026), and elapsed time to stone expulsion was significantly shorter (9±1.8 vs. 14±2.3 day, p=0.018) in the V. opulus group. The need for additional treatment (URS and ESWL) and analgesic requirement was less in the V. opulus group (9.4% vs. 20%, p=0.038 and 24.5% vs. 44%, p=0.042, respectively). Conclusion: V. opulus is an herbal treatment alternative that facilitates the passage of ureteral stones <10 mm. Prospective, randomized studies are needed to support these results. Cite this article as: Kızılay F, Ülker V, Çelik O, Özdemir T, Çakmak Ö, Can E, et al. The evaluation of the effectiveness of Gilaburu (Viburnum opulus L.) extract in the medical expulsive treatment of distal ureteral stones. Turk J Urol 2019; 45(Supp. 1): S63-S69.
20 November 2021 in Anatolian Bryology
Anzer vadisi ve çevresinin briyofit çeşitliliğinin ortaya çıkarılması amacıyla araştırma alanından Haziran ve Temmuz 2019 aylarında 33 istasyondan briyofit örnekleri toplanmıştır. Örneklerin incelenmesi sonucunda, 69 familya ve 135 cinse ait 286 karayosunu ve 52 ciğerotu taksonu olmak üzere toplamda 338 briyofit taksonu (tür, alttür ve varyete) tanımlanmıştır. Teşhis edilenler arasından Scapania obscura (Arn. & Jens.) Schiffn., Sphagnum fimbriatum Wilson, Sphagnum papillosum Lindb., Dicranella staphylina H.Whitehouse, ve Pohlia lescuriana (Sull.) Ochi, taksonlarının Türkiye’den ikinci kez kaydı verilmiştir. Ayrıca Rize'den ilk defa kaydı verilen briyofit taksonu sayısı 88 (9' u ciğerotu, 79' u karayosunu)’dir. Yapılan bu çalışma sonucunda Rize ili için yeni olan 88 taksonun eklenmesi ile Rize ilinden tespit edilmiş olan briyofit taksonu sayısı 424 olmuştur.
15 June 2021 in Anatolian Bryology
The main sources of atmospheric heavy metals deposition are agricultural activities, fossil fuels, central heating stations and the exhaust gases of motor vehicles. In this study, the total of 29 mosses samples were collected from contaminated points near the Isparta-Antalya, Burdur-Denizli, Burdur-Afyonkarahisar, Burdur-Fethiye (Muğla) and Burdur-Antalya highways (2-20m) and uncontaminated areas in 2012. Samples were analyzed by flame and graphite furnace atomic absorption spectrometry (AAS) later microwave digestion methods. The highest accumulation levels detected as µg.g−1 Fe (1419.02)>Zn (158.44)>Mn (362.77)>Ni (109.53)>Cr (60.51)>Pb (30.38)>Cd (35.866)>Cu (25.17) for mosses. Element levels are differ depending on moss species and the location of collecting localities.
16 June 2025 in Folia Medica
Xanthogranulomatous pyelonephritis (XGP) is a rare and severe chronic inflammatory condition of the kidney. XGP’s exact etiology remains unclear, although it is frequently associated with chronic urinary obstruction and infections within the urinary tract. Superinfections such as Escherichia coli, Proteus mirabilis, and occasionally Pseudomonas species typically cause XGP. Documented cases of Raoultella ornithinolytica (R. ornithinolytica) infections in humans, particularly within the urinary tract, are limited. However, advancements in diagnostic techniques are expected to increase the detection of such rare pathogens. To the best of our knowledge, currently, there is no evidence in the literature indicating that this pathogen is responsible for XGP. We present a case of XGP in which we isolated R. ornithinolytica and discuss its treatment in the current literature.
30 September 2025 in International Neurourology Journal
Purpose: This study aimed to determine whether urinary secretory immunoglobulin A (sIgA) levels differ between patients with bladder pain syndrome/interstitial cystitis (BPS/IC) and healthy controls, and to assess whether urinary sIgA is linked to mucosal immune mechanisms that may contribute to BPS/IC pathophysiology.Methods: A single-center, cross-sectional study was conducted between April and June 2020 at the Department of Urology, Ege University Faculty of Medicine. Forty female patients with BPS/IC and 40 healthy controls were enrolled. Symptom severity in the BPS/IC group was evaluated using the O’Leary-Sant Interstitial Cystitis Symptom and Problem Index. Patients with active urogenital infections, a history of bladder cancer, or prior pelvic radiotherapy were excluded. Urine samples were collected in sterile containers, centrifuged, and stored at -80°C before sIgA measurement using a commercial enzyme-linked immunosorbent assay kit. Correlations between continuous variables were examined with Spearman rank correlation coefficients.Results: Urinary sIgA levels were not significantly different between the BPS/IC group (mean±standard deviation: 0.96±1.5 μg/mL) and healthy controls (0.53±0.7 μg/mL) (P=0.173). Subgroup analyses within the BPS/IC cohort showed that smokers had significantly lower urinary sIgA levels (median [range], 0.001 [0.000–0.082] μg/mL) compared with nonsmokers (median [range], 0.720 [0.000–6.850] μg/mL) (P=0.004). Conversely, patients with cardiac comorbidities had significantly higher urinary sIgA levels (median [range], 0.820 [0.100–6.850] μg/mL) than those without cardiac disease (median [range], 0.213 [0.000–2.300] μg/mL) (P=0.015).Conclusions: Although no significant differences in urinary sIgA levels were observed between BPS/IC patients and healthy controls, subgroup analyses identified associations with smoking and cardiac comorbidities. These findings suggest that sIgA may be relevant to BPS/IC pathophysiology and highlight the potential of mucosal immune biomarkers. Larger studies are warranted to further clarify the role of sIgA in BPS/IC.